fluconazole has been researched along with Disseminated Fungal Infection in 41 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Posaconazole is superior to fluconazole (FLU) and itraconazole (ITRA) in the prevention of invasive fungal diseases (IFDs) in neutropenic patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS)." | 7.85 | Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain. ( Aragón, B; Cámara, R; Gozalbo, I; Grau, S; Jurado, M; Sanz, J, 2017) |
| "Fluconazole was confirmed to be an acceptable prophylactic agent early after allogeneic HSCT in appropriately selected patients." | 5.48 | Antifungal prophylaxis with fluconazole in allogeneic stem cell transplantation recipients who had prior invasive aspergillosis with subsequent complete resolution by computed tomography. ( Akahoshi, Y; Gomyo, A; Harada, N; Hayakawa, J; Ishihara, Y; Kako, S; Kameda, K; Kanda, Y; Kawamura, K; Kikuchi, M; Kimura, SI; Kusuda, M; Nakasone, H; Sakamoto, K; Sato, M; Tamaki, M; Terasako-Saito, K; Ugai, T; Wada, H, 2018) |
| "Posaconazole is superior to fluconazole (FLU) and itraconazole (ITRA) in the prevention of invasive fungal diseases (IFDs) in neutropenic patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS)." | 3.85 | Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain. ( Aragón, B; Cámara, R; Gozalbo, I; Grau, S; Jurado, M; Sanz, J, 2017) |
| " Our research indicated that the application of fluconazole did not result in intolerable adverse reactions in patients." | 3.01 | The efficacy and safety of fluconazole in preventing invasive fungal infection in very low birth weight infants: a systematic review and meta-analysis. ( Xie, J; Zeng, J; Zheng, S, 2023) |
| "Although invasive fungal infections (IFIs) contribute to substantial morbidity and mortality in liver transplant recipients, only a few randomized studies analyzed the results of antifungal prophylaxis with echinocandins." | 2.94 | A Multicenter, Randomized, Open-Label Study to Compare Micafungin with Fluconazole in the Prophylaxis of Invasive Fungal Infections in Living-Donor Liver Transplant Recipients. ( Choi, DL; Joh, JW; Kang, WH; Kim, JD; Kim, JM; Kim, MS; Kwon, CHD; Lee, KW; Lee, SG; Song, GW; Suh, KS; Yi, NJ, 2020) |
| "Quizartinib is an oral, highly potent and selective next-generation FMS-like tyrosine kinase 3 (FLT3) inhibitor under investigation in patients with FLT3-internal tandem duplication-mutated acute myeloid leukaemia." | 2.90 | Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite. ( Gammon, G; Kankam, M; Li, J; Trone, D, 2019) |
| "The epidemiology of invasive fungal infections (IFIs) in immunocompromised individuals has changed over the last few decades, partially due to the increased use of antifungal agents to prevent IFIs." | 2.66 | Breakthrough invasive fungal infections: Who is at risk? ( Chen, SC; Cornely, OA; Hoenigl, M; Jenks, JD; Thompson, GR, 2020) |
| "Invasive fungal infections are a potentially life-threatening complication in immunocompromised patients." | 2.66 | Efficacy and safety of posaconazole for the prevention of invasive fungal infections in immunocompromised patients: a systematic review with meta-analysis and trial sequential analysis. ( Ching, SM; Divya, G; Loo, YS; Menon, RK; Veettil, SK; Wong, PS; Wong, TY, 2020) |
| "Fluconazole was the only antifungal agent available in all institutions." | 1.91 | The Argentinian landscape of mycological diagnostic capacity and treatment accessibility. ( Caeiro, JP; Cornely, OA; Riera, F; Salmanton-García, J, 2023) |
| "To develop an approach to predict invasive fungal infections in ALL patients who accepted posaconazole prophylaxis." | 1.62 | Posaconazole and fluconazole prophylaxis during induction therapy for pediatric acute lymphoblastic leukemia. ( Bai, J; Huang, M; Li, R; Liu, A; Liu, J; Liu, Y; Zhang, T, 2021) |
| "Antifungal prophylaxis to prevent invasive fungal infections (IFI) is widely used following lung transplantation, but the optimal strategy remains unclear." | 1.62 | Evaluation of targeted versus universal prophylaxis for the prevention of invasive fungal infections following lung transplantation. ( Fitzgerald, LJ; Kauffman, CA; Linder, KA; Miceli, MH; Patel, TS; Richards, BJ, 2021) |
| "Rapid and reliable exclusion of invasive fungal infections (IFI) by markers able to avoid unnecessary empirical antifungal treatment is still a critical unmet clinical need." | 1.56 | Quantification of 1,3-β-d-glucan by Wako β-glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study. ( Alteri, C; Bielli, A; Brioschi, P; Cairoli, R; Cento, V; Colombo, J; De Gasperi, A; Gasparini, LE; Gatti, M; Lepera, V; Lombardi, G; Mancini, V; Mazza, E; Merli, M; Moioli, MC; Orcese, CA; Perno, CF; Puoti, M; Torri, S; Vismara, C, 2020) |
| "Implementation of a targeted FPP utilizing static dosing of fluconazole 400 mg × 14 days to those that meet high-risk criteria significantly reduces invasive fungal infection after liver transplant." | 1.51 | A targeted fungal prophylaxis protocol with static dosed fluconazole significantly reduces invasive fungal infection after liver transplantation. ( Andes, DR; Descourouez, JL; Fernandez, LA; Foley, DP; Jorgenson, MR; Leverson, GE; Marka, NA; Smith, JA, 2019) |
| "Isavuconazole is a recent extended-spectrum triazole with activity against yeasts." | 1.51 | Isavuconazole MIC distribution of 29 yeast species responsible for invasive infections (2015-2017). ( Boullié, A; Bretagne, S; Desnos-Ollivier, M; Dromer, F; Gautier, C; Lortholary, O, 2019) |
| "Fluconazole was confirmed to be an acceptable prophylactic agent early after allogeneic HSCT in appropriately selected patients." | 1.48 | Antifungal prophylaxis with fluconazole in allogeneic stem cell transplantation recipients who had prior invasive aspergillosis with subsequent complete resolution by computed tomography. ( Akahoshi, Y; Gomyo, A; Harada, N; Hayakawa, J; Ishihara, Y; Kako, S; Kameda, K; Kanda, Y; Kawamura, K; Kikuchi, M; Kimura, SI; Kusuda, M; Nakasone, H; Sakamoto, K; Sato, M; Tamaki, M; Terasako-Saito, K; Ugai, T; Wada, H, 2018) |
| " However, the ideal dosage of fluconazole has never been tested." | 1.48 | A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogeneic stem cell transplantation from a HLA identical sibling. ( Bramanti, S; Carlo-Stella, C; Casari, E; Castagna, L; Crocchiolo, R; De Philippis, C; Mariotti, J; Morabito, L; Pocaterra, D; Rimondo, A; Santoro, A; Sarina, B; Tordato, F, 2018) |
| "Objective: Invasive fungal infections (IFI) in bone marrow transplant (BMT) recipients are common and lethal." | 1.48 | The Role of Fluconazole Prophylaxis Regimen and the Regimes Chosen by the Patient’s Risk of Fungal Infection in Reducing\ the Infection Rate after Bone Marrow Transplantation ( Habibzadeh, A; Hajfathali, A; Hosseini, MH; Mehdizadeh, M; Pourghasemian, M, 2018) |
| "Here, we present a case of Crohn's disease with gastrointestinal cryptococcosis that resembled exacerbation of Crohn's disease." | 1.48 | Disseminated cryptococcosis in Crohn's disease: a case report. ( Angkasekwinai, N; Chavapradit, N, 2018) |
| "We analyzed multiple myeloma (MM) patients receiving chemotherapy in a prospective multicenter study." | 1.43 | Epidemiology and treatment of invasive fungal diseases in patients with multiple myeloma: findings from a multicenter prospective study from China. ( Huang, H; Huang, X; Li, J; Li, Y; Liu, J; Liu, L; Liu, Z; Lu, J; Ma, J; Ouyang, J; Ren, H; Song, Y; Wang, C; Wang, J; Xiao, Y; Yu, L; Zhou, D; Zhou, J, 2016) |
| "Of a total of 17 (8." | 1.43 | Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high-risk liver transplantation recipients: A propensity score analysis. ( Aguado, JM; Bodro, M; Carratalá, J; Casafont, F; Cervera, C; Fariñas, C; Fortún, J; Fresco, G; Gavaldá, J; Goikoetxea, J; Len, O; Martín-Dávila, P; Montejo, M; Moreno, A; Muñoz, P; Muriel, A; Pozo, JC; Silva, JT; Torre-Cisneros, J; Vena, A, 2016) |
| "Patients with acute myeloid leukemia (AML) during induction chemotherapy and those who receive allogeneic hematopoietic stem cell transplantation (HSCT) are at higher risk of invasive fungal infections (IFI)." | 1.43 | Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation. ( Audisio, E; Aversa, F; Bruno, B; Busca, A; Candoni, A; Delia, M; Monaco, F; Mordini, N; Pagano, L; Passera, R; Vacca, A, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 24 (58.54) | 24.3611 |
| 2020's | 17 (41.46) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, Y | 1 |
| Dong, G | 1 |
| Li, H | 1 |
| Liu, N | 1 |
| Zhang, W | 1 |
| Sheng, C | 1 |
| Pfaller, MA | 2 |
| Carvalhaes, CG | 2 |
| DeVries, S | 2 |
| Huband, MD | 1 |
| Castanheira, M | 2 |
| Rhomberg, PR | 1 |
| Liu, Y | 2 |
| Lan, C | 1 |
| Qin, S | 1 |
| Qin, Z | 1 |
| Zhang, Z | 1 |
| Zhang, P | 1 |
| Cao, W | 1 |
| Guo, MB | 1 |
| Yan, ZZ | 1 |
| Wang, X | 2 |
| Xu, H | 1 |
| Guo, C | 1 |
| Hou, Z | 1 |
| Gong, P | 1 |
| Enger, K | 3 |
| Tonnar, X | 3 |
| Kotter, E | 3 |
| Bertz, H | 3 |
| Xie, J | 2 |
| Zeng, J | 1 |
| Zheng, S | 1 |
| Riera, F | 1 |
| Caeiro, JP | 1 |
| Cornely, OA | 4 |
| Salmanton-García, J | 1 |
| Jorgenson, MR | 1 |
| Descourouez, JL | 1 |
| Marka, NA | 1 |
| Leverson, GE | 1 |
| Smith, JA | 1 |
| Andes, DR | 1 |
| Fernandez, LA | 1 |
| Foley, DP | 1 |
| Xia, Z | 1 |
| Yu, H | 1 |
| Wang, C | 2 |
| Ding, X | 1 |
| Zhang, D | 1 |
| Tan, X | 1 |
| Chen, J | 1 |
| Hu, S | 1 |
| Yang, R | 1 |
| Xia, XH | 1 |
| Lin, L | 1 |
| Zi-Yu, H | 1 |
| Tey, A | 1 |
| Mohan, B | 1 |
| Cheah, R | 1 |
| Dendle, C | 1 |
| Gregory, G | 1 |
| Jenks, JD | 1 |
| Chen, SC | 1 |
| Thompson, GR | 1 |
| Hoenigl, M | 1 |
| Cento, V | 1 |
| Alteri, C | 1 |
| Mancini, V | 1 |
| Gatti, M | 1 |
| Lepera, V | 1 |
| Mazza, E | 1 |
| Moioli, MC | 1 |
| Merli, M | 1 |
| Colombo, J | 1 |
| Orcese, CA | 1 |
| Bielli, A | 1 |
| Torri, S | 1 |
| Gasparini, LE | 1 |
| Vismara, C | 1 |
| De Gasperi, A | 1 |
| Brioschi, P | 1 |
| Puoti, M | 1 |
| Cairoli, R | 1 |
| Lombardi, G | 1 |
| Perno, CF | 1 |
| Zhang, T | 1 |
| Bai, J | 1 |
| Huang, M | 1 |
| Li, R | 1 |
| Liu, A | 1 |
| Liu, J | 2 |
| Wong, TY | 1 |
| Loo, YS | 1 |
| Veettil, SK | 1 |
| Wong, PS | 1 |
| Divya, G | 1 |
| Ching, SM | 1 |
| Menon, RK | 1 |
| Linder, KA | 1 |
| Kauffman, CA | 1 |
| Patel, TS | 1 |
| Fitzgerald, LJ | 1 |
| Richards, BJ | 1 |
| Miceli, MH | 1 |
| Herity, LB | 1 |
| Cruz, OA | 1 |
| Aziz, MT | 1 |
| Cámara, R | 1 |
| Gozalbo, I | 1 |
| Jurado, M | 1 |
| Sanz, J | 1 |
| Aragón, B | 1 |
| Grau, S | 1 |
| Wang, Y | 1 |
| Xing, Y | 1 |
| Chen, L | 1 |
| Li, Y | 2 |
| Meng, T | 1 |
| Dong, W | 1 |
| Dong, Y | 1 |
| Akahoshi, Y | 1 |
| Kimura, SI | 1 |
| Gomyo, A | 1 |
| Hayakawa, J | 1 |
| Tamaki, M | 1 |
| Harada, N | 1 |
| Kusuda, M | 1 |
| Kameda, K | 1 |
| Ugai, T | 1 |
| Wada, H | 1 |
| Ishihara, Y | 1 |
| Kawamura, K | 1 |
| Sakamoto, K | 1 |
| Sato, M | 1 |
| Terasako-Saito, K | 1 |
| Kikuchi, M | 1 |
| Nakasone, H | 1 |
| Kako, S | 1 |
| Kanda, Y | 1 |
| Hazar, V | 1 |
| Karasu, GT | 1 |
| Uygun, V | 1 |
| Öztürk, G | 1 |
| Kiliç, SÇ | 1 |
| Küpesiz, A | 1 |
| Daloglu, H | 1 |
| Aksoylar, S | 1 |
| Atay, D | 1 |
| Ince, EÜ | 1 |
| Karakükçü, M | 1 |
| Özbek, N | 1 |
| Tayfun, F | 1 |
| Kansoy, S | 1 |
| Özyürek, E | 1 |
| Akçay, A | 1 |
| Gürsel, O | 1 |
| Haskologlu, S | 1 |
| Kaya, Z | 1 |
| Yilmaz, S | 1 |
| Tanyeli, A | 1 |
| Yesilipek, A | 1 |
| Sarina, B | 1 |
| Mariotti, J | 1 |
| Bramanti, S | 1 |
| Morabito, L | 1 |
| Crocchiolo, R | 1 |
| Rimondo, A | 1 |
| Tordato, F | 1 |
| Pocaterra, D | 1 |
| Casari, E | 1 |
| De Philippis, C | 1 |
| Carlo-Stella, C | 1 |
| Santoro, A | 1 |
| Castagna, L | 1 |
| Tang, L | 1 |
| Yang, XF | 1 |
| Qiao, M | 1 |
| Zhang, L | 1 |
| Tang, XW | 1 |
| Qiu, HY | 1 |
| Wu, DP | 1 |
| Sun, AN | 1 |
| Pourghasemian, M | 1 |
| Mehdizadeh, M | 1 |
| Hajfathali, A | 1 |
| Habibzadeh, A | 1 |
| Hosseini, MH | 1 |
| Damasceno-Escoura, AH | 1 |
| de Souza, ML | 1 |
| de Oliveira Nunes, F | 1 |
| Pardi, TC | 1 |
| Gazotto, FC | 1 |
| Florentino, DH | 1 |
| Mora, DJ | 1 |
| Silva-Vergara, ML | 1 |
| Chavapradit, N | 1 |
| Angkasekwinai, N | 1 |
| Beatty, NL | 1 |
| Hanzlik, TP | 1 |
| Connick, E | 1 |
| Desnos-Ollivier, M | 1 |
| Bretagne, S | 1 |
| Boullié, A | 1 |
| Gautier, C | 1 |
| Dromer, F | 1 |
| Lortholary, O | 1 |
| Kang, WH | 1 |
| Song, GW | 1 |
| Lee, SG | 1 |
| Suh, KS | 1 |
| Lee, KW | 1 |
| Yi, NJ | 1 |
| Joh, JW | 1 |
| Kwon, CHD | 1 |
| Kim, JM | 1 |
| Choi, DL | 1 |
| Kim, JD | 1 |
| Kim, MS | 1 |
| Li, J | 3 |
| Kankam, M | 1 |
| Trone, D | 1 |
| Gammon, G | 1 |
| Baptista, MI | 1 |
| Nona, J | 1 |
| Ferreira, M | 1 |
| Sampaio, I | 1 |
| Abrantes, M | 1 |
| Tomé, MT | 1 |
| Neto, MT | 1 |
| Barroso, R | 1 |
| Serelha, M | 1 |
| Virella, D | 1 |
| Tüfekçi, Ö | 1 |
| Yılmaz Bengoa, Ş | 1 |
| Demir Yenigürbüz, F | 1 |
| Şimşek, E | 1 |
| Karapınar, TH | 1 |
| İrken, G | 1 |
| Ören, H | 1 |
| Huang, H | 1 |
| Liu, L | 1 |
| Liu, Z | 1 |
| Lu, J | 1 |
| Ouyang, J | 1 |
| Song, Y | 1 |
| Zhou, D | 1 |
| Ren, H | 1 |
| Ma, J | 1 |
| Yu, L | 1 |
| Zhou, J | 1 |
| Wang, J | 1 |
| Xiao, Y | 1 |
| Huang, X | 1 |
| Fortún, J | 1 |
| Muriel, A | 1 |
| Martín-Dávila, P | 1 |
| Montejo, M | 1 |
| Len, O | 1 |
| Torre-Cisneros, J | 1 |
| Carratalá, J | 1 |
| Muñoz, P | 1 |
| Fariñas, C | 1 |
| Moreno, A | 1 |
| Fresco, G | 1 |
| Goikoetxea, J | 1 |
| Gavaldá, J | 1 |
| Pozo, JC | 1 |
| Bodro, M | 1 |
| Vena, A | 1 |
| Casafont, F | 1 |
| Cervera, C | 1 |
| Silva, JT | 1 |
| Aguado, JM | 1 |
| Vidya, KM | 1 |
| Rao, UK | 1 |
| Nittayananta, W | 1 |
| Liu, H | 1 |
| Owotade, FJ | 1 |
| Giannella, M | 1 |
| Bartoletti, M | 1 |
| Morelli, M | 1 |
| Cristini, F | 1 |
| Tedeschi, S | 1 |
| Campoli, C | 1 |
| Tumietto, F | 1 |
| Bertuzzo, V | 1 |
| Ercolani, G | 1 |
| Faenza, S | 1 |
| Pinna, AD | 1 |
| Lewis, RE | 1 |
| Viale, P | 1 |
| Park, S | 1 |
| Kim, K | 1 |
| Jang, JH | 1 |
| Kim, SJ | 1 |
| Kim, WS | 1 |
| Chung, DR | 1 |
| Kang, CI | 1 |
| Peck, KR | 1 |
| Jung, CW | 1 |
| Solano, C | 1 |
| Slavin, M | 1 |
| Shaul, AJ | 1 |
| Marks, DI | 1 |
| Cordonnier, C | 1 |
| Pagliuca, A | 1 |
| Cragin, L | 1 |
| Jarque, I | 1 |
| Garcia-Vidal, C | 1 |
| Sorensen, S | 1 |
| Vanness, DJ | 1 |
| Charbonneau, C | 1 |
| Barrueta, JA | 1 |
| Peral, C | 1 |
| De Salas-Cansado, M | 1 |
| Bow, EJ | 1 |
| Busca, A | 1 |
| Candoni, A | 1 |
| Audisio, E | 1 |
| Passera, R | 1 |
| Bruno, B | 1 |
| Monaco, F | 1 |
| Mordini, N | 1 |
| Vacca, A | 1 |
| Delia, M | 1 |
| Aversa, F | 1 |
| Pagano, L | 1 |
| Durán Graeff, L | 1 |
| Seidel, D | 1 |
| Vehreschild, MJ | 1 |
| Hamprecht, A | 1 |
| Kindo, A | 1 |
| Racil, Z | 1 |
| Demeter, J | 1 |
| De Hoog, S | 1 |
| Aurbach, U | 1 |
| Ziegler, M | 1 |
| Wisplinghoff, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Open Label, Non-inferiority Study of Micafungin Versus Fluconazole for the Korean Prevention of Invasive Fungal Disease in Living Donor Liver Transplant Recipients[NCT01974375] | Phase 3 | 172 participants (Anticipated) | Interventional | 2012-08-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for fluconazole and Disseminated Fungal Infection
| Article | Year |
|---|---|
Efficacy of anti-fungal agents for invasive fungal infection prophylaxis in liver transplant recipients: A network meta-analysis.
Topics: Anidulafungin; Antifungal Agents; Echinocandins; Fluconazole; Humans; Invasive Fungal Infections; It | 2022 |
The efficacy and safety of fluconazole in preventing invasive fungal infection in very low birth weight infants: a systematic review and meta-analysis.
Topics: Antifungal Agents; Fluconazole; Humans; Infant, Newborn; Infant, Very Low Birth Weight; Invasive Fun | 2023 |
[Efficacy and safety of fluconazole in prophylaxis of invasive fungal infections in very low birth weight infants: a Meta analysis].
Topics: Antifungal Agents; Fluconazole; Humans; Infant, Newborn; Infant, Very Low Birth Weight; Invasive Fun | 2020 |
Breakthrough invasive fungal infections: Who is at risk?
Topics: Adrenal Cortex Hormones; Antifungal Agents; Aspergillus; Candida; Central Venous Catheters; Echinoca | 2020 |
Efficacy and safety of posaconazole for the prevention of invasive fungal infections in immunocompromised patients: a systematic review with meta-analysis and trial sequential analysis.
Topics: Antifungal Agents; Candidiasis; Fluconazole; Humans; Immunocompromised Host; Invasive Fungal Infecti | 2020 |
Choosing Optimal Antifungal Agents To Prevent Fungal Infections in Nonneutropenic Critically Ill Patients: Trial Sequential Analysis, Network Meta-analysis, and Pharmacoeconomic Analysis.
Topics: Antifungal Agents; Caspofungin; Cost-Benefit Analysis; Critical Illness; Echinocandins; Economics, P | 2017 |
Oral mycoses and other opportunistic infections in HIV: therapy and emerging problems - a workshop report.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Candida; Candidiasis, Oral; Carrier State; | 2016 |
3 trials available for fluconazole and Disseminated Fungal Infection
| Article | Year |
|---|---|
A Multicenter, Randomized, Open-Label Study to Compare Micafungin with Fluconazole in the Prophylaxis of Invasive Fungal Infections in Living-Donor Liver Transplant Recipients.
Topics: Antifungal Agents; End Stage Liver Disease; Fluconazole; Hematopoietic Stem Cell Transplantation; Hu | 2020 |
Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite.
Topics: Administration, Oral; Adolescent; Adult; Antifungal Agents; Area Under Curve; Benzothiazoles; Cytoch | 2019 |
Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients.
Topics: Adult; Antifungal Agents; Echinocandins; Female; Fluconazole; Hematopoietic Stem Cell Transplantatio | 2016 |
31 other studies available for fluconazole and Disseminated Fungal Infection
| Article | Year |
|---|---|
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
Topics: Animals; Apoptosis; Candida albicans; Cell Cycle; Cell Line, Tumor; Histone Deacetylase 6; Histone D | 2018 |
Elderly versus nonelderly patients with invasive fungal infections: species distribution and antifungal resistance, SENTRY antifungal surveillance program 2017-2019.
Topics: Aged; Antifungal Agents; Drug Resistance, Fungal; Echinocandins; Fluconazole; Humans; Invasive Funga | 2022 |
Impact of COVID-19 on the antifungal susceptibility profiles of isolates collected in a global surveillance program that monitors invasive fungal infections.
Topics: Animals; Antifungal Agents; Candida glabrata; Candida parapsilosis; Candida tropicalis; COVID-19; Dr | 2022 |
Design, synthesis and antifungal activities of novel triazole derivatives with selenium-containing hydrophobic side chains.
Topics: Animals; Antifungal Agents; Fluconazole; Humans; Invasive Fungal Infections; Mammals; Selenium; Tria | 2022 |
Sequential low-dose CT thorax scans to determine invasive pulmonary fungal infection incidence after allogeneic hematopoietic cell transplantation.
Topics: Antifungal Agents; Fluconazole; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Invasive | 2023 |
Sequential low-dose CT thorax scans to determine invasive pulmonary fungal infection incidence after allogeneic hematopoietic cell transplantation.
Topics: Antifungal Agents; Fluconazole; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Invasive | 2023 |
Sequential low-dose CT thorax scans to determine invasive pulmonary fungal infection incidence after allogeneic hematopoietic cell transplantation.
Topics: Antifungal Agents; Fluconazole; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Invasive | 2023 |
Sequential low-dose CT thorax scans to determine invasive pulmonary fungal infection incidence after allogeneic hematopoietic cell transplantation.
Topics: Antifungal Agents; Fluconazole; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Invasive | 2023 |
The Argentinian landscape of mycological diagnostic capacity and treatment accessibility.
Topics: Animals; Antifungal Agents; Argentina; Fluconazole; Invasive Fungal Infections; Itraconazole | 2023 |
A targeted fungal prophylaxis protocol with static dosed fluconazole significantly reduces invasive fungal infection after liver transplantation.
Topics: Aged; Antifungal Agents; Clinical Protocols; Drug Administration Schedule; Female; Fluconazole; Huma | 2019 |
Genomic and transcriptome identification of fluconazole-resistant genes for Trichosporon asahii.
Topics: Antifungal Agents; Biosynthetic Pathways; Drug Resistance, Fungal; Ergosterol; Female; Fluconazole; | 2020 |
Disseminated Lomentospora prolificans infection in a patient on idelalisib-rituximab therapy for relapsed chronic lymphocytic leukaemia.
Topics: Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance | 2020 |
Quantification of 1,3-β-d-glucan by Wako β-glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study.
Topics: Aged; Antifungal Agents; beta-Glucans; Caspofungin; Diagnostic Tests, Routine; Female; Fluconazole; | 2020 |
Posaconazole and fluconazole prophylaxis during induction therapy for pediatric acute lymphoblastic leukemia.
Topics: Antibiotic Prophylaxis; Antifungal Agents; Child; Child, Preschool; Female; Fluconazole; Humans; Ind | 2021 |
Evaluation of targeted versus universal prophylaxis for the prevention of invasive fungal infections following lung transplantation.
Topics: Antifungal Agents; Fluconazole; Humans; Invasive Fungal Infections; Lung Transplantation; Micafungin | 2021 |
Evaluation of a primary antifungal prophylaxis protocol for preventing invasive mold infections after allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Antifungal Agents; Fluconazole; Hematopoietic Stem Cell Transplantation; Humans; Invasive Fun | 2022 |
Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain.
Topics: Adult; Aged; Antifungal Agents; Cost-Benefit Analysis; Female; Fluconazole; Humans; Invasive Fungal | 2017 |
Antifungal prophylaxis with fluconazole in allogeneic stem cell transplantation recipients who had prior invasive aspergillosis with subsequent complete resolution by computed tomography.
Topics: Adolescent; Adult; Antibiotic Prophylaxis; Antifungal Agents; Aspergillosis; Feasibility Studies; Fe | 2018 |
Risks and outcomes of invasive fungal infections in pediatric allogeneic hematopoietic stem cell transplant recipients receiving fluconazole prophylaxis: a multicenter cohort study by the Turkish Pediatric Bone Marrow Transplantation Study Group.
Topics: Adolescent; Antibiotic Prophylaxis; Child; Child, Preschool; Female; Fluconazole; Follow-Up Studies; | 2019 |
A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogeneic stem cell transplantation from a HLA identical sibling.
Topics: Adolescent; Adult; Aged; Antibiotic Prophylaxis; Antifungal Agents; Dose-Response Relationship, Drug | 2018 |
Posaconazole vs. voriconazole in the prevention of invasive fungal diseases in patients with haematological malignancies: A retrospective study.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Child; China; Cost-Benefit Analysis; Female; Fluconazole | 2018 |
The Role of Fluconazole Prophylaxis Regimen and the Regimes Chosen by the Patient’s Risk of Fungal Infection in Reducing\
the Infection Rate after Bone Marrow Transplantation
Topics: Adolescent; Adult; Aged; Antifungal Agents; Bone Marrow Transplantation; Chemical and Drug Induced L | 2018 |
Epidemiological, Clinical and Outcome Aspects of Patients with Cryptococcosis Caused by Cryptococcus gattii from a Non-endemic Area of Brazil.
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Brazil; Cryptococcosis; Cryptococcus gattii; DNA, Fu | 2019 |
Disseminated cryptococcosis in Crohn's disease: a case report.
Topics: Amphotericin B; Antifungal Agents; Crohn Disease; Cryptococcosis; Disease Progression; Female; Fluco | 2018 |
West African Man with a Cavitary Pneumonia and Cutaneous Nodule.
Topics: Adult; Antibodies, Fungal; Arizona; Biopsy; Coccidioides; Coccidioidomycosis; Fluconazole; Humans; I | 2019 |
Isavuconazole MIC distribution of 29 yeast species responsible for invasive infections (2015-2017).
Topics: Antifungal Agents; Fluconazole; Humans; Invasive Fungal Infections; Microbial Sensitivity Tests; Nit | 2019 |
Invasive fungal infection in neonatal intensive care units: a multicenter survey.
Topics: Amphotericin B; Antifungal Agents; Cross Infection; Drug Resistance, Fungal; Female; Fluconazole; Ge | 2016 |
Management of Invasive Fungal Infections in Pediatric Acute Leukemia and the Appropriate Time for Restarting Chemotherapy.
Topics: Adolescent; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Prescho | 2015 |
Epidemiology and treatment of invasive fungal diseases in patients with multiple myeloma: findings from a multicenter prospective study from China.
Topics: Adolescent; Adult; Aged; Antifungal Agents; China; Female; Fluconazole; Humans; Incidence; Invasive | 2016 |
Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high-risk liver transplantation recipients: A propensity score analysis.
Topics: Adult; Aged; Alanine Transaminase; Antifungal Agents; Aspergillosis; Bilirubin; Caspofungin; Cohort | 2016 |
Antifungal prophylaxis in liver transplant recipients: one size does not fit all.
Topics: Antibiotic Prophylaxis; Antifungal Agents; Aspergillus; Candida; Female; Fluconazole; Humans; Incide | 2016 |
Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.
Topics: Adult; Antifungal Agents; Cost-Benefit Analysis; Decision Support Techniques; Fluconazole; Hematopoi | 2017 |
Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
Topics: Adolescent; Adult; Aged; Allografts; Antifungal Agents; Blood Donors; Female; Fluconazole; Hematopoi | 2016 |
Invasive infections due to Saprochaete and Geotrichum species: Report of 23 cases from the FungiScope Registry.
Topics: Adolescent; Adult; Aged; Amphotericin B; Antifungal Agents; Echinocandins; Female; Fluconazole; Fung | 2017 |